Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299849 | 1.00 | GRIA1 (0.39) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL299722 | 1.00 | GRIA1 (0.39) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL299772 | 1.00 | GRIA1 (0.39) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL300159 | 1.00 | GRIA1 (0.39) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL300304 | 0.97 | GRIA1 (0.36) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL300345 | 0.92 | — | — | |
| SCHEMBL299825 | 0.81 | — | — | |
| SCHEMBL29229351 | 0.81 | GRIA1 (0.42) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL7606619 | 0.78 | GRIA1 (0.43) | GRIA1CA2CA1PPARAALDH1A1 | |
| SCHEMBL15562309 | 0.77 | GRIA1 (0.41) | GRIA1CA2CA1PPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501897-B1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF SE (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-7807836-B2 | Preparation of perylen-3,4:9,10-tetracarboxylic dianhydride and also of naphtalene-1,8-dicarboximides | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080161569-A1 | PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1501897-A1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091345-A1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161569-A1 | PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES | CLIC1, PNPO, CLIC4 | GRIA1 3467/4885CA2 25/4885CA1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.